MD Anderson researchers will present clinical trial results of promising combination therapies for a variety of cancers at the 2019 American Society of Clinical Oncology (ASCO) annual meeting, which begins Friday in Chicago.
The ASCO session brings together more than 32,000 oncology professionals from around the world to share the latest cancer treatment and oncology research results. Among highlighted findings from hundreds of...
Researchers at The University of Texas MD Anderson Cancer Center have shown how pretreatment clonal complexity in pancreatic tumor cells leads...
Researchers at MD Anderson Cancer Center have defined a new oncogene for B-cell lymphomas. The cancer-causing gene, known as heterogeneous...
The Therapeutics Discovery division at MD Anderson Cancer Center has advanced a new small-molecule inhibitor of cancer metabolism to Phase I clinical trials. This new drug candidate marks the fourth novel therapeutic brought from concept to clinical trial by Therapeutics Discovery, a drug-discovery engine built within the walls of MD Anderson to eliminate the bottlenecks that hamper traditional drug development.
The drug candidate...
Immunology research to investigate the mechanisms of a new aerosol treatment, which induces an innate immune response to protect against pathogens...